Literature DB >> 32735734

Codeployment of a percutaneous edge-to-edge mitral valve repair device and a ventriculoseptal defect occluder device to address complex mitral regurgitation with leaflet perforation.

Dylan R Addis1, Mark Law2, Gregory von Mering3, Mustafa Ahmed4.   

Abstract

An 80-year-old male with severe, complex mitral regurgitation (MR) after recent transcatheter aortic valve replacement presented in heart failure for percutaneous mitral valve repair and possible tricuspid valve repair. Transesopheageal echocardiography (TEE) demonstrated mixed Carpentier Types 1 and 2 components with annular dilation, two leaflet perforations, and excessive leaflet motion (P2 flail). There were three distinct MR jets appreciated reflecting a central coaptation defect and two posterior mitral valve leaflet perforations emanating from a cystic dilatation. Under TEE guidance transseptal puncture and percutaneous edge-to-edge mitral valve repair was performed with a MitraClip XTR device (Abbott, IL). A 10 mm Amplatzer Muscular VSD Occluder (Abbott, Abbott Park, IL) was deployed to close one of the perforations on the posterior leaflet with a significant reduction in MR severity. Attempts at crossing the remaining defect were unsuccessful and the procedure was concluded. The patient recovered uneventfully and transthoracic echocardiography on postoperative day (POD) 1 and again on POD 34 demonstrated normal systolic dominance on pulmonary venous Doppler interrogation, mild to moderate MR, and a mean transvalvular gradient of 5 mmHg. Both devices appeared firmly attached and stable. This is the first documented use of a VSD occluder device in this clinical scenario. Management of complex MR with an approach combining edge-to-edge repair for a central coaptation defect and leaflet flail with codeployment of a VSD occluder device to address a perforated leaflet is feasible and can achieve durable results.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  Amplatzer; MitraClip; transseptal; transvenous mitral valve repair

Year:  2020        PMID: 32735734      PMCID: PMC7680454          DOI: 10.1002/ccd.29147

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  6 in total

1.  Percutaneous closure of a native mitral valve perforation.

Authors:  Sonia Velasco; Mariano Larman; Marian Eneriz
Journal:  Rev Esp Cardiol       Date:  2010-05       Impact factor: 4.753

2.  Transseptal Anchored Vascular Plug Closure of Mitral Valve Perforation.

Authors:  Elena K Grant; Dennis W Kim; William L Border; Stamatios Lerakis; Vasilis Babaliaros; Robert N Vincent
Journal:  JACC Cardiovasc Interv       Date:  2017-02-15       Impact factor: 11.195

3.  Percutaneous Repair of Mitral Valve Leaflet Perforation.

Authors:  Tiberio M Frisoli; Adam Greenbaum; William W O'Neill; Dee Dee Wang; Marvin Eng
Journal:  JACC Cardiovasc Interv       Date:  2018-12-26       Impact factor: 11.195

4.  Effects of Mechanical Ventilation on Heart Geometry and Mitral Valve Leaflet Coaptation During Percutaneous Edge-to-Edge Mitral Valve Repair.

Authors:  Johannes Patzelt; Yingying Zhang; Peter Seizer; Harry Magunia; Andreas Henning; Veronika Riemlova; Tara A E Patzelt; Marc Hansen; Michael Haap; Reimer Riessen; Henning Lausberg; Tobias Walker; Joerg Reutershan; Christian Schlensak; Christian Grasshoff; Dan I Simon; Peter Rosenberger; Juergen Schreieck; Meinrad Gawaz; Harald F Langer
Journal:  JACC Cardiovasc Interv       Date:  2015-12-23       Impact factor: 11.195

5.  Retrograde transcatheter closure of anterior mitral valve leaflet perforation.

Authors:  Berke Sengun; Işıl Yıldırım; Ömer Yıldız; Alpay Çeliker
Journal:  Ann Pediatr Cardiol       Date:  2019 Sep-Dec

6.  Bail-out use of the Amplatzer Septal Occluder for treatment of acute iatrogenic leaflet perforation during the MitraClip procedure in a patient with functional mitral regurgitation.

Authors:  Adrian Kłapyta; Jerzy Pręgowski; Zbigniew Chmielak; Piotr Szymański; Adam Witkowski; Marcin Demkow
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-09-21       Impact factor: 1.426

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.